Cancer immunotherapy

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

By Merav Burstein / October 28, 2024 / Comments Off on Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

HAIFA, Israel – October 28, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today announced that the Israel Innovation Authority (“IIA”) will fund Pluri’s collaboration with the Bar-Ilan University Research and Development Company Ltd., (“BIRAD”), the commercial arm of Bar-Ilan University, to support the continued…

Read More
BIRAD - Research and Development Co. Ltd

Novel strategy for targeting glycosylated patterns on cancer cells using CAR-cells

By Assaf Sagiv / December 17, 2020 / Comments Off on Novel strategy for targeting glycosylated patterns on cancer cells using CAR-cells

The Problem Immunotherapy has become a revolution in the area of cancer treatment. Compared to the traditional methods, such as invasive surgeries, radiation, and chemotherapy, immunotherapy is more specific and less toxic to patients. Chimeric antigen receptor (CAR)-engineered T cell therapy is considered a promising approach since it has shown remarkable ability to eliminate tumors…

Read More

Recent Posts

Recent Comments

    Categories

    Archives